GLP-1 Menstrual Cycle Changes: Late Periods, Spotting, Heavy Bleeding, and What to Track
Can semaglutide or tirzepatide affect your period? Understand the new menstrual safety signals, other likely causes, pregnancy precautions, and when bleeding needs medical care.
A changed period is worth tracking—but it does not prove your GLP-1 caused it
New safety-signal research makes menstrual changes harder to dismiss, but rapid weight change, low energy intake, PCOS, pregnancy, contraception, and unrelated gynecologic conditions can produce the same symptoms.
Searches such as “semaglutide late period,” “Zepbound spotting,” and “GLP-1 heavy period” describe a real counseling gap. Menstrual changes are not among the familiar nausea-and-constipation talking points, so people often find community anecdotes before they find a careful explanation.
A July 2026 study using reports submitted to the FDA Adverse Event Reporting System found disproportionate reporting signals for several menstrual events. Semaglutide had signals for heavy menstrual bleeding, bleeding between periods, menstrual clots, infrequent periods, and cycles without ovulation; tirzepatide had signals for bleeding between periods and menstrual clots. This is a reason to investigate and counsel—not proof that either drug caused an individual event or a measure of how often these events occur.
Key highlights
- •The newest evidence is a pharmacovigilance signal, not a cause-and-effect trial or incidence estimate.
- •Weight change and improved insulin resistance can regularize cycles in some people with PCOS while under-fueling or other conditions can disrupt cycles in others.
- •A missed period with any chance of pregnancy calls for a pregnancy test and prompt contact with the prescribing clinician.
What the new menstrual safety-signal study actually found
Researchers reviewed FDA adverse-event reports through March 2026 for female patients ages 12 to 55 and used disproportionality and Bayesian methods to identify menstrual events reported more often than expected. Semaglutide produced the broadest signal profile. Tirzepatide produced narrower signals, while liraglutide did not produce significant signals in that analysis.
The limitation is crucial: FAERS is a spontaneous reporting system. It cannot confirm that a medication caused an event, calculate the true event rate, or reliably separate the medication from weight loss, an underlying condition, contraception, pregnancy, or reporting bias. Reports are also more likely to be submitted after a symptom receives public attention. The finding should move menstrual health into the clinical conversation, not turn every changed cycle into a confirmed drug reaction.
Why GLP-1 users can see opposite cycle changes
Some people report a late or missed period, spotting, heavier bleeding, new clots, or a shorter or longer cycle. Others—especially some people with obesity, insulin resistance, or PCOS—see previously irregular cycles become more regular. Those experiences are not necessarily contradictory because treatment changes several variables at once: body weight, insulin sensitivity, appetite, energy intake, and sometimes ovulatory function.
A 2026 semaglutide study in 96 women with a PCOS-like metabolic ovarian syndrome reported improved ovulation and cycle regularity after six months, and broader reviews describe emerging evidence of improved ovulation in PCOS. That potential benefit does not establish semaglutide as a menstrual treatment for everyone. It does mean that a more regular period—or an unexpected pregnancy after fertility improves—is also clinically relevant.
Do not overlook weight loss, under-fueling, PCOS, and other causes
A GLP-1 can be part of the timeline without being the only explanation. Rapid weight change, a sustained energy deficit, very low fat intake, intense training, stress, thyroid disease, elevated prolactin, perimenopause, fibroids, polyps, PCOS, infection, pregnancy, and changes in hormonal contraception can all alter bleeding or cycle timing. Functional hypothalamic amenorrhea guidelines specifically treat low energy availability and weight loss as important contributors to absent periods.
This is why “my period changed after my dose increased” is useful data but not a diagnosis. The same dose increase may also have caused nausea, skipped meals, lower total intake, and faster weight loss. A clinician needs that context to distinguish a possible adverse drug effect from an indirect nutrition effect or a separate gynecologic problem.
Pregnancy and contraception change the urgency
If a period is late or missing and pregnancy is possible, take a pregnancy test and contact the prescribing clinician. Current Wegovy and Zepbound prescribing information says these medications should not be used during pregnancy; do not wait for the next routine appointment to disclose a positive test. Do not stop, restart, or change a dose based only on an internet guide—get individualized instructions from the prescriber.
Tirzepatide has an additional contraception warning. The official Zepbound label says it may reduce the effectiveness of oral hormonal contraceptives because of delayed gastric emptying. It advises switching to a non-oral contraceptive method or adding a barrier method for four weeks after starting Zepbound and for four weeks after each dose increase. Other GLP-1 products do not automatically share the same instruction, so check the label for the specific medication.
A useful menstrual and GLP-1 tracking checklist
Record the first and last day of bleeding; whether flow is lighter or heavier than usual; pad, tampon, cup, or disc changes; clots; spotting between periods; bleeding after sex; pain; dizziness; and the length of each cycle. Alongside that, log medication name, dose, injection date, recent dose changes, weight trend, vomiting or diarrhea, appetite, approximate food and protein intake, training volume, contraception changes, and pregnancy-test results when relevant.
Two or three cycles of consistent data can show whether a change was isolated, followed a dose escalation, or persisted despite stable dosing and intake. Bring a short summary to the clinician rather than a pile of disconnected notes: what changed, when it began, how severe it was, what else changed at the same time, and whether pregnancy is possible. Tracking supports evaluation; it should never delay care for heavy bleeding or pregnancy concerns.
When bleeding needs prompt or emergency care
Seek urgent medical guidance for new heavy bleeding, repeated large clots, bleeding between periods that persists, severe pelvic or abdominal pain, fainting, marked weakness, or symptoms of anemia. The American College of Obstetricians and Gynecologists advises emergency care when bleeding soaks through a pad or tampon every hour for more than two hours in a row and is accompanied by chest pain, shortness of breath, lightheadedness, or dizziness.
Prompt evaluation is also appropriate for a positive pregnancy test, suspected pregnancy with pain or bleeding, or periods that stop without a clear explanation. These situations need more than symptom tracking because pregnancy complications, significant blood loss, and gynecologic conditions can require time-sensitive care.
What to ask your clinician instead of guessing
Ask whether the pattern is more consistent with the medication, the pace of weight loss, inadequate energy intake, a contraceptive interaction, PCOS-related ovulation changes, or another condition. Useful follow-up may include a pregnancy test, blood count, thyroid testing, medication review, nutrition assessment, or gynecologic evaluation depending on the symptoms and history.
The practical goal is not to prove or disprove a GLP-1 effect from one cycle. It is to protect reproductive health while keeping treatment decisions grounded in evidence. A stable nutrition and tracking system also supports metabolic independence: it makes it easier to see whether the body is being under-fueled during active loss and gives the care team better information before any dose or transition-off decision.
Frequently asked questions
Can semaglutide or tirzepatide change your period?
A 2026 FDA adverse-event reporting analysis found signals for heavy bleeding, bleeding between periods, clots, infrequent periods, and anovulatory cycles with semaglutide, plus signals for bleeding between periods and clots with tirzepatide. The study cannot prove causation or show how common the events are. Weight loss, low energy intake, PCOS, pregnancy, contraception, and other conditions can also change periods.
Can semaglutide make your period late or cause a missed period?
A late or missed period can occur during the same period as GLP-1 treatment, but medication causation is not established. Pregnancy, rapid weight loss, inadequate intake, stress, PCOS, thyroid disease, perimenopause, and other causes should be considered. If pregnancy is possible, take a test and contact the prescribing clinician.
Can GLP-1 medications make periods more regular?
They may improve cycle regularity and ovulation in some people with obesity, insulin resistance, or PCOS. That can also increase the possibility of conception. The evidence does not support using a GLP-1 as a universal menstrual treatment, and these medications should not be used during pregnancy.
Does Zepbound affect birth control pills?
The official Zepbound prescribing information says tirzepatide may reduce the effectiveness of oral hormonal contraceptives. It advises using a non-oral contraceptive or adding a barrier method for four weeks after starting and for four weeks after every dose increase. Confirm the plan with the prescribing clinician.
When is heavy menstrual bleeding an emergency?
ACOG advises emergency care if bleeding soaks through a pad or tampon every hour for more than two consecutive hours and you also have chest pain, shortness of breath, lightheadedness, or dizziness. Fainting, severe pain, suspected pregnancy with bleeding, or rapidly worsening symptoms also need urgent evaluation.
Sources
Evidence review includes the July 2026 FDA adverse-event reporting analysis, reproductive-health reviews, an Endocrine Society amenorrhea guideline, ACOG bleeding guidance, and current official Wegovy and Zepbound prescribing information. Safety signals cannot establish causation or incidence.
- 2026 FAERS study: GLP-1 receptor agonists and menstrual events
- 2026 semaglutide study of irregular menses and anovulation
- 2026 review of GLP-1 receptor agonists and fertility
- Endocrine Society guideline: functional hypothalamic amenorrhea
- ACOG guidance on abnormal uterine bleeding
- Official Wegovy prescribing information
- Official Zepbound prescribing information
A changed period is worth tracking—but it does not prove your GLP-1 caused it
New safety-signal research makes menstrual changes harder to dismiss, but rapid weight change, low energy intake, PCOS, pregnancy, contraception, and unrelated gynecologic conditions can produce the same symptoms.
Track symptoms and cycle context free →